2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Expression profiles from CD14+ monocytes in PD patients with GBA mutations

G. Riboldi, E. Udine, E. Navarro, M. Parks, B. Henderson, K. Sharma, T. Sikder, M. Zhuang, J. Crary, S. Frucht, T. Raj (New York, NY, USA)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Factitious Disorder Imposed on Another mimicking a Dopamine Dysregulation Syndrome

DRC. Carneiro, MS. Sousa, ASM. Morgadinho, CJ. Januário (Coimbra, Portugal)

Psychiatric Manifestations  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Factors that interfere in the functionality according to Functional Independence Measure in people with Parkinson’s Disease.

E. Libardi, M. Piemonte, E. Guelfi, E. Okamoto (São Paulo, Brazil)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Factors underlying reduced aerobic capacity in Huntington disease

A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Familial Creutzfeldt-Jakob disease with D178N and Met129Val

N. Omer, E. Kahana, S. Simchoni, A. Bar-Shira, T. Naiman, A. Orr-Urtreger, B. Aminov, D. Klepikov, N. Giladi, N. Bregman (Tel Aviv, Israel)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Feasibility and acceptability of a therapist-delivered physical activity coaching intervention for people with premanifest and early stage Huntington’s Disease and Parkinson’s Disease

K. Long Ms, M. Caciula Phd, C. Friel Edd, L. Quinn Edd (New York City, NY, USA)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3